← Back to patent-cliff list
Olanzapine transdermal patch (Starton Therapeutics)
Tier C — Watch / tradeOlanzapine transdermal patch (Starton Therapeutics)
Starton Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：DRD1, 5-HT2, DRD2
Indications (approved)：Nausea, 呕吐
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Olanzapine transdermal patch (Starton Therapeutics)?
Approved indications include: Nausea, 呕吐.
When does the Olanzapine transdermal patch (Starton Therapeutics) patent expire?
No public expiry year is available for Olanzapine transdermal patch (Starton Therapeutics) yet; this page updates once verified.
How do I get a quote for Olanzapine transdermal patch (Starton Therapeutics) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06